See more : Careplus Group Berhad (0163.KL) Income Statement Analysis – Financial Results
Complete financial analysis of COMPASS Pathways plc (CMPS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of COMPASS Pathways plc, a leading company in the Medical – Care Facilities industry within the Healthcare sector.
- Filter Vision Public Company Limited (FVC.BK) Income Statement Analysis – Financial Results
- MSP Recovery, Inc. (MSPRZ) Income Statement Analysis – Financial Results
- Sougou Shouken Co.,Ltd. (7850.T) Income Statement Analysis – Financial Results
- Karmarts Public Company Limited (KAMART.BK) Income Statement Analysis – Financial Results
- De Grey Mining Limited (DGMLF) Income Statement Analysis – Financial Results
COMPASS Pathways plc (CMPS)
About COMPASS Pathways plc
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 0.00 |
| Gross Profit | -242.94K | -329.80K | -174.98K | -112.00K | -63.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 87.52M | 65.05M | 44.03M | 23.37M | 12.56M | 8.92M |
| General & Administrative | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.40M | 45.35M | 39.19M | 28.03M | 8.62M | 3.59M |
| Other Expenses | 0.00 | -14.42M | -9.65M | -4.25M | -2.73M | -2.68M |
| Operating Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
| Cost & Expenses | 136.92M | 95.98M | 73.57M | 47.15M | 18.45M | 10.54M |
| Interest Income | 0.00 | 0.00 | 40.00 | 319.00 | 73.00 | 0.00 |
| Interest Expense | 2.21M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 242.94K | 329.80K | 174.98K | 112.00K | 63.00K | 22.00K |
| EBITDA | -123.80M | -110.40M | -83.22M | -47.04M | -18.39M | -10.52M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -136.92M | -110.40M | -83.22M | -51.39M | -21.18M | -12.50M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 19.24M | 19.31M | 11.68M | -8.91M | 1.58M | -716.00K |
| Income Before Tax | -117.68M | -91.10M | -71.54M | -60.30M | -19.60M | -13.22M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 780.00K | 408.00K | 199.00K | 32.00K | 15.00K | -716.00K |
| Net Income | -118.46M | -91.51M | -71.74M | -60.33M | -19.61M | -13.22M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
| EPS Diluted | -2.32 | -2.16 | -1.79 | -1.68 | -0.90 | 0.00 |
| Weighted Avg Shares Out | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
| Weighted Avg Shares Out (Dil) | 51.03M | 42.44M | 40.00M | 35.93M | 21.72M | 17.26B |
Are Medical Stocks Lagging COMPASS Pathways (CMPS) This Year?
Scrutinizing Psychedelic Stocks
3 Biotech Stocks Aiming to Reinvent Mental Health Treatment
3 Big Trends Shaking Up Psychedelic Stocks
COMPASS Pathways plc (CMPS) Q3 2022 Earnings Call Transcript
COMPASS Pathways plc to announce third quarter 2022 financial results on 3 November 2022
COMPASS Pathways PLC Sponsored ADR (CMPS) Upgraded to Buy: What Does It Mean for the Stock?
Is Now a Good Time to Invest In Psychedelics Stocks?
Buying These 2 Battered Growth Stocks Right Now Could Be Brilliant
Compass Pathways (CMPS): The McDonald's of Psychedelics?
Source: https://incomestatements.info
Category: Stock Reports